Status:
COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the blood pressure lowering effect and safety of aliskiren 150 mg used in combination with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with essential hypertension
- Patients who are eligible and able to participate in the study Exclusion Criteria
- Severe hypertension
- History or evidence of a secondary form of hypertension
- History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
504 Patients enrolled
Trial Details
Trial ID
NCT00219076
Start Date
February 1 2005
Last Update
May 18 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
2
Investigative Centers, Germany